NCT05896683View on ClinicalTrials.gov

A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

September 1, 2023

Study Completion Date

September 1, 2023

Conditions
Healthy
Interventions
DRUG

Lazertinib

Lazertinib will be administered orally.

Trial Locations (1)

2650

SGS Belgium NV, Edegem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT05896683 - A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants | Biotech Hunter | Biotech Hunter